"Tetrahydronaphthalenes" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Partially saturated 1,2,3,4-tetrahydronaphthalene compounds.
| Descriptor ID |
D013764
|
| MeSH Number(s) |
D02.455.426.559.847.638.960 D04.615.638.960
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Tetrahydronaphthalenes".
Below are MeSH descriptors whose meaning is more specific than "Tetrahydronaphthalenes".
This graph shows the total number of publications written about "Tetrahydronaphthalenes" by people in this website by year, and whether "Tetrahydronaphthalenes" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 2002 | 2 | 1 | 3 |
| 2003 | 1 | 0 | 1 |
| 2005 | 1 | 0 | 1 |
| 2006 | 1 | 0 | 1 |
| 2007 | 5 | 0 | 5 |
| 2008 | 0 | 1 | 1 |
| 2009 | 1 | 0 | 1 |
| 2010 | 1 | 1 | 2 |
| 2011 | 1 | 0 | 1 |
| 2012 | 3 | 1 | 4 |
| 2014 | 2 | 0 | 2 |
| 2015 | 0 | 2 | 2 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Tetrahydronaphthalenes" by people in Profiles.
-
Open-label, phase II, multicenter study of lasofoxifene plus abemaciclib for treating women with metastatic ER+/HER2- breast cancer and an ESR1 mutation after disease progression on prior therapies: ELAINE 2. Ann Oncol. 2023 12; 34(12):1131-1140.
-
Elacestrant and the Promise of Oral SERDs. J Clin Oncol. 2022 10 01; 40(28):3227-3229.
-
Targeting the Notch pathway: A potential therapeutic approach for desmoid tumors. Cancer. 2015 Nov 15; 121(22):4088-96.
-
Restless legs syndrome: clinical presentation diagnosis and treatment. Sleep Med. 2015 Jun; 16(6):678-90.
-
Effects of long-term treatment with rotigotine transdermal system on dyskinesia in patients with early-stage Parkinson's disease. Parkinsonism Relat Disord. 2014 Dec; 20(12):1345-51.
-
Bexarotene reduces network excitability in models of Alzheimer's disease and epilepsy. Neurobiol Aging. 2014 Sep; 35(9):2091-5.
-
Final results of phase II trial of doxorubicin HCl liposome injection followed by bexarotene in advanced cutaneous T-cell lymphoma. Ann Oncol. 2014 Jan; 25(1):206-10.
-
Small-molecule inhibitors of cathepsin L incorporating functionalized ring-fused molecular frameworks. Bioorg Med Chem Lett. 2013 May 01; 23(9):2801-7.
-
Clinical outcomes and biomarker profiles of elderly pretreated NSCLC patients from the BATTLE trial. J Thorac Oncol. 2012 Nov; 7(11):1645-52.
-
The combination of tamoxifen and the rexinoid LG100268 prevents ER-positive and ER-negative mammary tumors in p53-null mammary gland mice. Cancer Prev Res (Phila). 2012 Oct; 5(10):1195-202.